Condition (MeSH)
Preleukemia
ClinicalTrials.gov lists 14 trials for Preleukemia or a narrower condition beneath it. Center for International Blood and Marrow Transplant Research has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
14 of the 14 trials are tagged with Preleukemia itself; the rest are tagged with a narrower condition beneath it.
When did Preleukemia trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 1 |
| 2021 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2008 | 2 |
| 2006 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Preleukemia trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 5 |
| Phase 1/2 | 3 |
| Phase 2 | 4 |
| Not applicable | 1 |
| Expanded access | 1 |
How many Preleukemia trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Completed | 6 |
| Terminated | 2 |
| No longer available | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Preleukemia trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Center for International Blood and Marrow Transplant Research | 2 |
| BlossomHill Therapeutics | 1 |
| Constellation Pharmaceuticals | 1 |
| Novartis Pharmaceuticals | 1 |
| Orca Biosystems, Inc. | 1 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Preleukemia? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Melphalan | 4 |
| Cytoxan | 2 |
| Busulfan | 2 |
| MESNA | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 3 |
| Alemtuzumab s.c. | 2 |
| IR Tacrolimus | 2 |
| Post-Transplant Cyclophosphamide | 2 |
| Total Body Irradiation | 2 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Preleukemia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 44 | 1 |
| Hepatobiliary disease NOS | 30 | 1 |
| Anaemia | 26 | 1 |
| Febrile neutropenia | 20 | 1 |
| Blast cell count increased | 18 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Preleukemia? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Growth modulation of human leukemic, preleukemic, and myeloma progenitor cells by L-ascorbic acid. | The American journal of clinical nutrition | 1991 | Yes |
| 1,25-Dihydroxyvitamin D3: in vivo and in vitro effects on human preleukemic and leukemic cells. | Cancer treatment reports | 1985 | Yes |
| Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. | Proceedings of the National Academy of Sciences of the United States of America | 1980 | Yes |
| The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. | Blood | 2009 | No |
| The human major histocompatibility complex and childhood leukemia: an etiological hypothesis based on molecular mimicry. | Blood cells, molecules & diseases | 2009 | No |
Showing 5 of 7 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.